The FDA approved a subcutaneous injection version of Bristol Myers Squibb nivolumab and hyaluronidase-nvhy for the treatment of several cancers including melanoma, non-small cell lung cancer and renal ...

(Nivolumab + relatlimab) is under clinical development by Bristol-Myers Squibb and currently in Phase III for Non-Small Cell Lung Cancer.

Nivolumab is under clinical development by Bristol-Myers Squibb and currently in Phase III for Peritoneal Cancer.

Becomes the first subcutaneously administered PD-1 inhibitor.

More research is needed to refine treatment strategies and identify predictive biomarkers for patient selection, according to researchers.

CARsgen Therapeutics Holdings Limited, a company focused on innovative CAR T-cell therapies for the treatment of hematologic ...

Bristol Myers Squibb (BMY) announced Friday that the U.S. Food and Drug Administration has approved Opdivo Qvantig (nivolumab and ...

On December 27, 2024, subcutaneous nivolumab (Opdivo Qvantig) was approved by the FDA in all previously approved adult solid ...

The Food and Drug Administration announced it has approved nivolumab and hyaluronidase-nvhy, Opdivo Qvantig, from Bristol Myers (BMY) Squibb, ...

This year’s most-read oncology content of 2024 includes topics on clinical trials, drug access, vaping and lung cancer, and ...

During a Case-Based Roundtable® event, David H. Ilson, MD, PhD, discussed the outcomes of the CheckMate 649, CheckMate 648, ...

Number 3: Sandoz's biosimilar denosumab (Jubbonti/Wyost) has demonstrated analytical, pharmacokinetic, pharmacodynamic, and ...